Immune Design Corp. (NASDAQ:IMDZ) – Research analysts at Jefferies Group reduced their Q3 2017 earnings per share (EPS) estimates for shares of Immune Design Corp. in a report released on Thursday. Jefferies Group analyst M. Raycroft now forecasts that the biotechnology company will post earnings per share of ($0.64) for the quarter, down from their prior estimate of ($0.62). Jefferies Group currently has a “Buy” rating and a $18.00 target price on the stock. Jefferies Group also issued estimates for Immune Design Corp.’s Q4 2017 earnings at ($0.66) EPS, FY2017 earnings at ($2.37) EPS, FY2018 earnings at ($2.43) EPS, FY2019 earnings at ($0.17) EPS and FY2020 earnings at ($1.25) EPS.

Immune Design Corp. (NASDAQ:IMDZ) last released its earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.54) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.65) by $0.11. The firm had revenue of $0.73 million during the quarter, compared to analysts’ expectations of $1.50 million. Immune Design Corp. had a negative net margin of 324.33% and a negative return on equity of 59.14%. TRADEMARK VIOLATION NOTICE: “Immune Design Corp. to Post Q3 2017 Earnings of ($0.64) Per Share, Jefferies Group Forecasts (IMDZ)” was first posted by Daily Political and is owned by of Daily Political. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright law. The original version of this story can be viewed at https://www.dailypolitical.com/2017/08/08/immune-design-corp-to-post-q3-2017-earnings-of-0-64-per-share-jefferies-group-forecasts-imdz.html.

A number of other research firms have also issued reports on IMDZ. Zacks Investment Research upgraded shares of Immune Design Corp. from a “hold” rating to a “buy” rating and set a $11.00 price target on the stock in a report on Tuesday, July 18th. BidaskClub lowered shares of Immune Design Corp. from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Cowen and Company reiterated a “buy” rating on shares of Immune Design Corp. in a research note on Tuesday, June 6th. Finally, ValuEngine upgraded shares of Immune Design Corp. from a “strong sell” rating to a “sell” rating in a research note on Thursday, June 22nd. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. Immune Design Corp. currently has an average rating of “Buy” and a consensus target price of $14.50.

Shares of Immune Design Corp. (NASDAQ:IMDZ) opened at 10.60 on Monday. The firm has a 50-day moving average of $9.47 and a 200 day moving average of $7.03. Immune Design Corp. has a 1-year low of $4.50 and a 1-year high of $13.05. The stock’s market capitalization is $271.56 million.

In other Immune Design Corp. news, Director Lewis W. Coleman bought 12,000 shares of the firm’s stock in a transaction on Tuesday, July 11th. The stock was bought at an average cost of $9.05 per share, with a total value of $108,600.00. Following the completion of the transaction, the director now directly owns 40,000 shares of the company’s stock, valued at approximately $362,000. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, insider Wayne Gombotz sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 1st. The stock was sold at an average price of $11.43, for a total transaction of $114,300.00. Following the completion of the sale, the insider now directly owns 33,054 shares of the company’s stock, valued at $377,807.22. The disclosure for this sale can be found here. Insiders acquired 30,000 shares of company stock valued at $272,760 over the last three months. Insiders own 42.90% of the company’s stock.

A number of hedge funds have recently bought and sold shares of IMDZ. FMR LLC increased its stake in Immune Design Corp. by 0.4% in the first quarter. FMR LLC now owns 445,152 shares of the biotechnology company’s stock valued at $3,027,000 after buying an additional 1,699 shares in the last quarter. Trexquant Investment LP increased its stake in Immune Design Corp. by 15.5% in the second quarter. Trexquant Investment LP now owns 31,152 shares of the biotechnology company’s stock valued at $304,000 after buying an additional 4,174 shares in the last quarter. Rhumbline Advisers increased its stake in Immune Design Corp. by 53.9% in the second quarter. Rhumbline Advisers now owns 19,694 shares of the biotechnology company’s stock valued at $192,000 after buying an additional 6,896 shares in the last quarter. TIAA CREF Investment Management LLC increased its stake in Immune Design Corp. by 18.9% in the first quarter. TIAA CREF Investment Management LLC now owns 45,574 shares of the biotechnology company’s stock valued at $310,000 after buying an additional 7,236 shares in the last quarter. Finally, Bank of America Corp DE increased its stake in Immune Design Corp. by 123.3% in the first quarter. Bank of America Corp DE now owns 15,246 shares of the biotechnology company’s stock valued at $104,000 after buying an additional 8,418 shares in the last quarter. 50.61% of the stock is owned by institutional investors.

Immune Design Corp. Company Profile

Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.

Earnings History and Estimates for Immune Design Corp. (NASDAQ:IMDZ)

Receive News & Ratings for Immune Design Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design Corp. and related companies with MarketBeat.com's FREE daily email newsletter.